EMA Authorised: Blincyto (blinatumomab) — Amgen Europe B.V.

View source ↗

Summary

The EMA authorised Blincyto (blinatumomab) by Amgen Europe B.V. for precursor cell lymphoblastic leukemia/lymphoma, designated as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: Amgen Europe B.V.. Decision date: 27/11/2025. Orphan medicine